Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorMedical University of Gdańsk-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorPiotrowska, Anna-
Autor(es): dc.creatorBeserra, Fernando Pereira-
Autor(es): dc.creatorWierzbicka, Justyna Marta-
Autor(es): dc.creatorNowak, Joanna Irena-
Autor(es): dc.creatorŻmijewski, Michał Aleksander-
Data de aceite: dc.date.accessioned2025-08-21T22:19:08Z-
Data de disponibilização: dc.date.available2025-08-21T22:19:08Z-
Data de envio: dc.date.issued2022-04-28-
Data de envio: dc.date.issued2022-04-28-
Data de envio: dc.date.issued2021-12-23-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3389/fonc.2021.763895-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/223199-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/223199-
Descrição: dc.descriptionRegardless of the recent groundbreaking introduction of personalized therapy, melanoma continues to be one of the most lethal skin malignancies. Still, a substantial proportion of patients either fail to respond to the therapy or will relapse over time, representing a challenging clinical problem. Recently, we have shown that vitamin D enhances the effectiveness of classical chemotherapeutics in the human malignant melanoma A375 cell line. In search for new combination strategies and adjuvant settings to improve melanoma patient outcomes in the current study, the effects of cediranib (AZD2171), an oral tyrosine kinase inhibitor of VEGFR1-3, PDGFR, and c-KIT, used in combination either with 1,25(OH)2D3 or with low-calcemic analog calcipotriol were tested on four human malignant melanoma cell lines (A375, MNT-1, RPMI-7951, and SK-MEL-28). Melanoma cells were pretreated with vitamin D and subsequently exposed to cediranib. We observed a marked decrease in melanoma cell proliferation (A375 and SK-MEL-28), G2/M cell cycle arrest, and a significant decrease in melanoma cell mobility in experimental conditions used (A375). Surprisingly, concurrently with a very desirable decrease in melanoma cell proliferation and mobility, we noticed the upregulation of VEGFR2 at both protein and mRNA levels. No effect of vitamin D was observed in MNT-1 and RPMI-7951 melanoma cells. It seems that vitamin D derivatives enhance cediranib efficacy by modulation of VEGFR2 expression in melanoma cells expressing VEGFR2. In conclusion, our experiments demonstrated that vitamin D derivatives hold promise as novel adjuvant candidates to conquer melanoma, especially in patients suffering from vitamin D deficiency. However, further extensive research is indispensable to reliably assess their potential benefits for melanoma patients.-
Descrição: dc.descriptionDepartment of Histology Faculty of Medicine Medical University of Gdańsk-
Descrição: dc.descriptionInstitute of Biosciences São Paulo State University-
Descrição: dc.descriptionInstitute of Biosciences São Paulo State University-
Idioma: dc.languageen-
Relação: dc.relationFrontiers in Oncology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectanti-angiogenic therapy-
Palavras-chave: dc.subjectcalcipotriol-
Palavras-chave: dc.subjectcediranib-
Palavras-chave: dc.subjectmelanoma-
Palavras-chave: dc.subjectVEGFR-
Palavras-chave: dc.subjectVEGFR inhibitors-
Palavras-chave: dc.subjectvitamin D-
Título: dc.titleVitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.